Biogen (BIIB) Acquisitions (2010 - 2023)

Biogen (BIIB) posted Acquisitions of $590.5 million for Q4 2023, up 197.03% on a QoQ basis from $198.8 million in Q1 2015.

Analysis

Biogen (BIIB) Acquisitions (2010 - 2023) Analysis & Trends

Biogen has reported Acquisitions for 5 years, with the latest figure at $590.5 million in Q4 2023.

On a quarterly basis, Acquisitions changed N/A year-over-year to $590.5 million in Q4 2023; TTM through Dec 2025 was $590.5 million, a 0.0% change from a year earlier, with the FY2024 full-year figure at $1.1 billion, down 84.48% from the prior year.
Acquisitions was $590.5 million for Q4 2023 at Biogen, up from $198.8 million in the prior quarter.
The five-year high for Acquisitions was $590.5 million in Q4 2023, with the low at $590.5 million in Q4 2023.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Amgen	206.44 Bn	192.45 Bn	7.24 Bn	-
2	Gilead Sciences	179.97 Bn	176.79 Bn	6.22 Bn	11.21 Bn
3	Vertex Pharmaceuticals	130.57 Bn	122.72 Bn	2.84 Bn	-
4	Regeneron Pharmaceuticals	81.63 Bn	73.63 Bn	3.93 Bn	-
5	Argenx Se	60.34 Bn	55.16 Bn	1.37 Bn	-
6	Moderna	54.37 Bn	49.23 Bn	52.00 Mn	-
7	Alnylam Pharmaceuticals	33.07 Bn	29.76 Bn	992.69 Mn	-
8	Biogen	31.84 Bn	30.55 Bn	1.96 Bn	-
9	Roivant Sciences	29.49 Bn	29.49 Bn	1.16 Mn	-
10	Insmed	27.67 Bn	26.51 Bn	358.27 Mn	-

Historic Data

Download Data